NCT06970080RecruitingPhase 4
Therapeutic Relevance of Abnormal Airway Morphology in Asthma
Therapeutic Relevance of Abnormal Airway Morphology in Asthma: A Path to Optimized Management and Drug Development (AirPATH Study)
Source: ClinicalTrials.gov · Last updated 11 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be several reasons for this. One possibility is that inhaled medications fail to reach the intended areas within the lungs, due to structural abnormalities within the airways themselves. Much like road conditions or closures can impede the speed and efficiency of vehicle travel, factors such as airway narrowing or mucus blockages, which are common in asthma, can obstruct the passage of inhaled medications through the airways. Our team has now optimized advanced medical imaging techniques, including magnetic resonance imaging (MRI) and computed tomography (CT), required to investigate this. This study will use these imaging methods to visually assess and measure individual patients' airways and determine whether abnormal airway structures impact how well they respond to inhaled and orally delivered medications. We anticipate finding that abnormal airway structures make inhaled medications less effective, but that they do not affect the response to oral medications.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 242 (estimated)
- First submitted
- 17 Apr 2025
- Start date
- Jun 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- McMaster University
- Diseases
- Asthma
- NCT number
- NCT06970080
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 242
- From Jun 2025 to the primary completion date, Jun 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current smoker, defined as someone having smoked ≥1 cigarette/day (or vape/pipe/cigar/marijuana) for ≥30 days within 12 months prior to screening.
- Oral corticosteroids in past 1-month
- Biologic therapy in past 6-months
- Other pulmonary diseases (e.g., chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis) requiring treatment within 12 months prior to screening.
Other illness
- Unable to undergo MRI. Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist). Suffers from any physical, psychological, or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia.
Other
- Pregnant or breastfeeding
- Non-English speaking
- Unable to perform proper MDI technique during the screening period
Who the study is looking for
- Able and willing to provide written informed consent.
- Able and willing to comply with the study protocol.
- Males and females ≥ 18 years of age.
- Asthma diagnosed by a respiratory physician.
- Airway hyperresponsiveness (defined as methacholine PC20 ≤8mg/mL) and/or bronchodilator reversibility (defined as post-bronchodilator FEV1 improvement ≥200mL and 12%) in the last 6 months
- ACQ ≥1.5 during the screening period.
- Sputum eosinophils ≥3% and/or FeNO ≥35ppb during the screening period.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Joseph's Healthcare Hamilton Coordinator of this site? Confirm its status | Hamilton | Canada | Recruiting |
| Western University Coordinator of this site? Confirm its status | London | Canada | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.